EUVIMEDEUVIMED entdecken
Open Access

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Michael Melgar, Amadea Britton, Lauren E Roper, H Keipp Talbot, Sarah S Long, Camille N Kotton, Fiona P Havers

MMWR. Morbidity and Mortality Weekly Report · 21.07.2023 · 72 (29) · 793-801

DOI: 10.15585/mmwr.mm7229a4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, online erschienen am 21.07.2023. Verfasst von Michael Melgar und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections, Respiratory Tract Diseases. Die Arbeit wurde bisher 326-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a cause of severe respiratory illness in older adults. In May 2023, the Food and Drug Administration approved the first vaccines for prevention of RSV-associated lower respiratory tract disease in adults aged ≥60 years. Since May 2022, the Advisory Committee on Immunization Practices (ACIP) Respiratory Syncytial Virus Vaccines Adult Work Group met at least monthly to review available evidence regarding the safety, immunogenicity, and efficacy of these vaccines among adults aged ≥60 years. On June 21, 2023, ACIP voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. This report summarizes the body of evidence considered for this recommendation and provides clinical guidance for the use of RSV vaccines in adults aged ≥60 years. RSV vaccines have demonstrated moderate to high efficacy in preventing RSV-associated lower respiratory tract disease and have the potential to prevent substantial morbidity and mortality among older adults; postmarketing surveillance will direct future guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Tract DiseasesHumansUnited StatesAgedAdvisory CommitteesImmunizationVaccinationImmunization Schedule

Substanzen

Respiratory Syncytial Virus Vaccines

Zitieren

APA

Melgar, M., Britton, A., Roper, L. E., Talbot, H. K., Long, S. S., Kotton, C. N., & Havers, F. P. (2023). Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR. Morbidity and Mortality Weekly Report, 72(29), 793-801. https://doi.org/10.15585/mmwr.mm7229a4

Vancouver

Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR. Morbidity and Mortality Weekly Report. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4

BibTeX
@article{Melgar2023,
  author = {Melgar, Michael and Britton, Amadea and Roper, Lauren E and Talbot, H Keipp and Long, Sarah S and Kotton, Camille N and Havers, Fiona P},
  title = {Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  year = {2023},
  volume = {72},
  number = {29},
  pages = {793--801},
  doi = {10.15585/mmwr.mm7229a4}
}
Kostenlos starten →